Bristol Myers Squibb Q3 revenue $13.07B, beats $12.71B estimate

The beat is broad-based enough to matter: both the top line and adjusted EPS cleared consensus, and the raised full-year revenue range signals management sees the momentum carrying rather than a one-quarter blip. That combination — an earnings beat paired with a guidance lift — is the more durable signal for a large-cap pharma name, since it implies the underlying franchise is tracking ahead of internal plans, not just that costs were managed. The open question is whether the revised range holds through the fourth quarter, or whether it gets trimmed again as the year closes.